Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Sep. 30, 2023
Current assets:
Cash, cash equivalents and restricted cash	$ 69,399	$ 110,891
Available-for-sale securities, at fair value	367,272	292,735
Prepaid expenses	9,207	8,813
Other current assets	4,184	4,033
Total current assets	450,062	416,472
Property, plant and equipment, net	375,911	290,262
Intangible assets, net	8,987	10,262
Right-of-use assets	44,339	45,297
Other assets	4,460	3,259
Total Assets	883,759	765,552
Current liabilities:
Accounts payable	26,550	35,866
Accrued expenses	47,899	39,763
Accrued payroll and benefits	15,795	17,963
Lease liabilities	6,053	10,563
Deferred revenue	0	866
Other liabilities	417	435
Total current liabilities	96,714	105,456
Long-term liabilities:
Lease liabilities, net of current portion	112,040	104,608
Liability related to the sale of future royalties	336,031	268,326
Total long-term liabilities	448,071	372,934
Commitments and contingencies (Note 7)
Noncontrolling interest and stockholders’ equity:
Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 124,227 and 107,312 shares	217	200
Additional paid-in capital	1,786,304	1,300,395
Accumulated other comprehensive loss	(987)	(3,222)
Accumulated deficit	(1,454,987)	(1,026,030)
Total Arrowhead Pharmaceuticals, Inc. stockholders’ equity	330,547	271,343
Noncontrolling interest	8,427	15,819
Total noncontrolling interest and stockholders’ equity	338,974	287,162
Total Liabilities, Noncontrolling Interest and Stockholders’ Equity	$ 883,759	$ 765,552